The Dean Felsher Lab investigates how oncogenes initiate and sustain tumorigenesis to develop treatments, ranging from small molecule inhibitors to immunotherapies, aimed at improving outcomes across different metabolic diseases and cancer types including lymphoma, kidney cancer, hepatocellular carcinoma (HCC), breast cancer, and MYC-driven cancers.